Boston Scientific Corporation (NYSE:BSX – Get Free Report) crossed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $43.91 and traded as low as $43.51. Boston Scientific shares last traded at $43.7340, with a volume of 16,091,446 shares traded.
Analyst Upgrades and Downgrades
Several research firms have commented on BSX. Barclays dropped their price target on shares of Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating on the stock in a research note on Friday, October 30th. Wells Fargo & Company cut their price target on Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating on the stock in a report on Thursday, October 29th. Jefferies Financial Group downgraded Boston Scientific from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $60.00 to $46.00 in a research report on Wednesday, October 28th. Canaccord Genuity Group reduced their price objective on Boston Scientific from $66.00 to $48.00 and set a “buy” rating for the company in a research report on Thursday, October 29th. Finally, Piper Sandler decreased their price objective on Boston Scientific from $65.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $61.43.
View Our Latest Stock Report on Boston Scientific
Boston Scientific Stock Down 1.4%
The firm’s fifty day moving average is $43.91 and its two-hundred day moving average is $54.25. The firm has a market cap of $63.39 billion, a price-to-earnings ratio of 18.53, a P/E/G ratio of 1.31 and a beta of 0.60. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.81.
Boston Scientific (NYSE:BSX – Get Free Report) last released its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting the consensus estimate of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter last year, the company earned $0.75 EPS. Boston Scientific’s quarterly revenue was up 1.4% on a year-over-year basis. On average, sell-side analysts expect that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in BSX. BlackRock Inc. bought a new stake in Boston Scientific during the second quarter worth approximately $5,534,781,000. Primecap Management Co. CA acquired a new stake in Boston Scientific in the second quarter worth approximately $2,156,233,000. Janus Henderson Group PLC boosted its stake in Boston Scientific by 31.0% during the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock valued at $1,035,202,000 after purchasing an additional 3,907,981 shares in the last quarter. Amundi boosted its stake in Boston Scientific by 13.8% during the 1st quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock valued at $886,213,000 after purchasing an additional 1,707,754 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Boston Scientific by 25.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock valued at $871,702,000 after purchasing an additional 2,856,040 shares during the period. 89.07% of the stock is currently owned by institutional investors.
About Boston Scientific
Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.
Further Reading
- Five stocks we like better than Boston Scientific
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
